The stock of United Therapeutics Corporation (UTHR) formed an up wedge with $167.65 target or 5.00% above today’s $159.67 share price. The 9 months wedge indicates low risk for the $7.01B company. If the $167.65 …
Company insiders own 7.50% of the company’s stock. “United Therapeutics Co. (UTHR) to Post Q2 2017 …
Brokerages following United Therapeutics Corporation (NASDAQ:UTHR) demonstrate a mean target price of $135.111 on its stock. It is known after doing methodical evaluation on company. The high range is $229 while …
The stock now has an average rating of "Hold" and a consensus target price of $140.17. Shares of United Therapeutics (NASDAQ:UTHR) traded up 2.40% on Monday, reaching $150.23. Spark Therapeutics has a one …
United
Today's Most Active Call & Put Options of the S&P 500 » United Therapeutics Corp (UTHR) options are showing a volume of 5,204 contracts thus far today. That number of contracts represents approximately 520,400 …
University Teachers for Human Rights
Big-cap biotech United Therapeutics (UTHR) disappointed investors for the second quarter in a row Tuesday, as it missed Q2 estimates and its new drug launch continued to underwhelm. The stock hit a five-month low in …
Nationwide Fund Advsrs accumulated 199,926 shares or 0.09% of the stock. Public Employees Retirement …
Below is a three month price history chart comparing the stock performance of UTHR, versus EBS and ISIS. Special Offer: Find out what Dave Moenning is holding in the ETF Channel Flexible Growth Investment Portfolio …
AQR Capital Management LLC now owns 1,584,113 shares of the biotechnology company’s stock valued at $167,790,000 after buying an additional 277,266 shares during the period. Shares of United Therapeutics Co. …
The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the …